Abstract: DNA double-strand breaks (DSBs) are the most deleterious type of DNA damage, primarily induced by ionizing radiation (IR) and certain anticancer drugs. The DNA-dependent protein kinase (DNA-PK) complex, comprising the catalytic subunit (DNA-PKcs) and the Ku70/Ku80 heterodimer, acts as a critical molecular sensor for DSBs and drives repair through the non-homologous end joining (NHEJ) pathway. NU7441 (also known as KU-57788) is a highly potent and selective small-molecule inhibitor of DNA-PK developed to target this DNA damage response mechanism. By competitively binding to DNA-PKcs, NU7441 prevents DSB repair, thereby acting as a powerful radiosensitizer and chemosensitizer in cancer models. Structural studies have elucidated its precise binding mechanism within the hydrophobic pockets of DNA-PKcs, explaining its high selectivity over related kinases like ATM and ATR. Although its pharmacological profile has made it an indispensable tool for functional studies of DNA-PK, efforts to improve its water solubility and clinical viability have led to the development of several next-generation derivatives. This review summarizes the pharmacological activity, molecular mechanism, structure-activity relationship, limitations, and future perspectives of NU7441 in the context of cancer therapy.
1. Introduction
Ionizing radiation (IR) and various chemotherapeutic agents exert their biological and therapeutic effects primarily by inducing DNA damage. Among the various forms of DNA lesions, the DNA double-strand break (DSB) is considered the most deleterious[1]. In eukaryotic cells, DSBs are predominantly repaired through the non-homologous end joining (NHEJ) pathway, which is active throughout the cell cycle, particularly in the G1 and G0 phases[1].
A central component of the NHEJ pathway is the DNA-dependent protein kinase (DNA-PK), a complex composed of a large catalytic subunit (DNA-PKcs) and a DNA-targeting Ku80-Ku70 heterodimer[1]. DNA-PK acts as a molecular sensor that binds to and is activated by the ends of double-stranded DNA. Cells deficient in DNA-PKcs exhibit hypersensitivity to IR and DNA-damaging agents, making DNA-PK an attractive target for cancer therapy[1]. NU7441 (8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one) was developed as a highly potent and selective DNA-PK inhibitor, evolving from earlier phosphatidylinositol 3-kinase (PI3K) inhibitors such as LY294002 and NU7026, to augment cellular sensitivity to radiotherapy and chemotherapy[1].
2. Pharmacological Activity
NU7441 has been extensively utilized in functional studies of DNA-PK due to its robust pharmacological activity. In cellulo, NU7441 effectively sensitizes cultured cancer cells to ionizing radiation and the chemotherapeutic drug etoposide at a concentration of 0.5 µM, functioning in a strictly DNA-PKcs-dependent manner[1]. Furthermore, NU7441 has been shown to alleviate the toxicity of the PARP inhibitor olaparib in ATM-deficient cells, highlighting its complex role in modulating DNA damage response networks[1].
In vivo studies using tumor xenograft models have demonstrated that intraperitoneal (i.p.) administration of NU7441 at doses ranging from 10 to 25 mg/kg significantly potentiates tumor growth suppression when combined with radiation or chemotherapeutic drugs like etoposide[1]. These findings underscore its efficacy as a potent radio- and chemosensitizer.
3. Molecular Mechanism of Action
The primary mechanism of action of NU7441 involves the targeted inhibition of DNA-PKcs, which halts the recognition and processing stages of the NHEJ repair pathway[1]. By inhibiting DNA-PK, NU7441 prevents the repair of DSBs, leading to the accumulation of lethal DNA damage and subsequent cell death following exposure to IR or DNA-damaging agents[1].
NU7441 exhibits remarkable potency and selectivity for DNA-PK over other members of the PI3K-related kinase (PIKK) family. The half-maximal inhibitory concentration (IC50) of NU7441 for DNA-PK is 14 nM[1]. In contrast, its IC50 values for Ataxia-telangiectasia mutated (ATM) and ATM- and Rad3-related (ATR) kinases are greater than 100,000 nM, demonstrating exceptional selectivity. Its IC50 for mTOR is 1700 nM, and for PI3Kα it is 5000 nM, indicating that it is highly specific to DNA-PK compared to its structural predecessors[1].
4. Structure-Activity Relationship (SAR)
NU7441 was discovered through the systematic chemical modification of chromenone libraries, building upon the structural similarity of DNA-PK to PI3Ks[1]. The chemical structure of NU7441 includes a morpholine ring, a chromen-4-one core, and a dibenzothiophene group. Recent structural studies utilizing cryo-electron microscopy (cryo-EM) have provided deep insights into how NU7441 interacts with DNA-PKcs[1].
The cryo-EM data reveals that the chromen and morpholine groups of NU7441 are inserted into the deepest hydrophobic pocket of DNA-PKcs, which is formed by the amino acid residues Leu3751, Tyr3791, Ile3803, Leu3986, and Ile3940[1]. Simultaneously, the dibenzothiophene group is inserted into a secondary hydrophobic pocket formed by Met3729, Pro3735, and Leu3751[1]. These multiple, highly specific interactions between NU7441 and the DNA-PKcs binding pockets explain the compound's significantly higher affinity and selectivity for DNA-PKcs compared to earlier, less specific inhibitors like wortmannin or LY294002[1].
5. Current Limitations
While NU7441 is a highly potent and selective inhibitor that serves as an excellent tool compound for preclinical and functional studies, its translation into clinical practice has faced hurdles, primarily related to its physicochemical properties. A notable limitation of NU7441 is its poor water solubility, which impacts its pharmacokinetic profile and bioavailability[1]. To overcome this limitation, researchers had to modify the NU7441 scaffold to create derivatives, such as KU-0060648, specifically designed to increase water solubility for better in vivo and potential clinical application[1].
6. Future Perspectives
The development of NU7441 represents a critical milestone in the evolution of DNA-PK inhibitors. Its structural and functional validation has paved the way for the design of next-generation inhibitors. For instance, modifications of the NU7441 structure have led to the development of KU-0060648 (a dual DNA-PK/PI3K inhibitor), LTURM34 (where the chromenone structure was replaced by benzoxazinone to further increase selectivity), and NU5455 (an orally available derivative that shows potent in vivo efficacy without adverse effects in normal tissues)[1].
Furthermore, the recent elucidation of the DNA-PKcs/NU7441 complex structure via cryo-EM opens the door for advanced structure-guided drug design[1]. The insights gained from NU7441 have directly influenced the discovery of newer clinical candidates like M3814 and AZD7648, which are currently in phase 1 and 2 clinical trials. Future research will likely focus on optimizing these targeted therapies in combination with radiotherapy, chemotherapy, and immunotherapy to maximize tumor eradication while minimizing toxicity[1].
